目的评估甘精胰岛素联合那格列奈治疗初诊2型糖尿病的疗效及安全性.方法初次诊断的HbA 1 c>8.0%的2型糖尿病患者75例，给予甘精胰岛素联合那格列奈治疗12周，比较治疗前后空腹血糖(FBG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA 1 c)及胰岛功能的变化.结果治疗后所有患者血糖及HbA 1 c均明显下降(P<0.01)，餐后2 h胰岛素、C肽水平、胰岛素分泌指数较治疗前明显升高，胰岛素抵抗指数较治疗前显著降低.结论甘精胰岛素联合那格列奈治疗初诊2型糖尿病，能理想控制血糖且胰岛功能得到部分恢复.%Objective To evaluate the efficacy and safety of nateglinide combined with insulin glargine in treatment of the new patients with type 2 diabetes. Methods Eighty-five patients with newly diagnosed type 2 diabetes were treated by nateglinide with insulin glargine injection 12 weeks. The changes of Fasting blood glucose(FBG), 2 h postprandial blood glucose(2 hPG), glycosylated hemoglobin(HbA 1 c) and B cell function were observed before and after the treatment. Results The levels of FBG,2 hPG , HbA 1 c and insulin resistance index after treatment significantly decreased (P<0.01). while postprandial 2 h insulin level , postprandial 2 h C-peptide level(2 h CP) and insulin secrete index was significantly higher then before(P<0.01). Conclusion Nateglinide combined with insulin glargine in treatment of the new patients with type 2 diabetes can ideally control glucose and significantly restored pancreatic islet B-cell function, reducing sugar toxicity.
展开▼
